nach oben

NeuroMolecular Medicine

Erschienen in:

04.05.2021 | Review

Repurposing Vorinostat for the Treatment of Disorders Affecting Brain

verfasst von: K. V. Athira, Prashant Sadanandan, Sumana Chakravarty

Erschienen in: NeuroMolecular Medicine | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Based on the findings in recent years, we summarize the therapeutic potential of vorinostat (VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and strategies to improve drug efficacy and reduce side effects. Scientific evidences provide a strong case for the therapeutic utility of VOR in various disorders affecting brain, including stroke, Alzheimer’s disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, X‐linked adrenoleukodystrophy, epilepsy, Niemann-Pick type C disease, and neuropsychiatric disorders. Further elucidation of the neuroprotective and neurorestorative properties of VOR using proper clinical study designs could provide momentum towards its clinical application. To improve the therapeutic prospect, concerns on systemic toxicity and off-target actions need to be addressed along with the improvement in formulation and delivery aspects, especially with respect to solubility, permeability, and pharmacokinetic properties. Newer approaches in this regard include poly(ethylene glycol)-b-poly(dl-lactic acid) micelles, VOR-pluronic F127 micelles, encapsulation of iron complexes of VOR into PEGylated liposomes, human serum albumin bound VOR nanomedicine, magnetically guided layer-by-layer assembled nanocarriers, as well as convection-enhanced delivery. Even though targeting specific class or isoform of HDAC is projected as advantageous over pan-HDAC inhibitor like VOR, in terms of adverse effects and efficacy, till clinical validation, the idea is debated. As the VOR treatment-related adverse changes are mostly found reversible, further optimization of the therapeutic strategies with respect to dose, dosage regimen, and formulations of VOR could propel its clinical prospects.

Abel, T., & Zukin, R. S. (2008). Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Current Opinion in Pharmacology, 8(1), 57–64PubMedPubMedCentralCrossRef

Alarcón, J. M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E. R., & Barco, A. (2004). Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron, 42(6), 947–959PubMedCrossRef

Almeida, S., Gao, F., Coppola, G., & Gao, F.-B. (2016). Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. Neurobiology of Aging, 42, 35–40PubMedPubMedCentralCrossRef

Alquezar, C., Esteras, N., de la Encarnación, A., Moreno, F., de Munain, A. L., & Martín-Requero, Á. (2015). Increasing progranulin levels and blockade of the ERK1/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia. European Neuropsychopharmacology, 25(3), 386–403PubMedCrossRef

Athira, K. V., Bandopadhyay, S., Samudrala, P. K., Naidu, V., Lahkar, M., & Chakravarty, S. (2020). An overview of the heterogeneity of major depressive disorder: Current knowledge and future prospective. Current Neuropharmacology, 18(3), 168–187PubMedPubMedCentralCrossRef

Athira, K., Madhana, R. M., Lahkar, M., Sinha, S., & Naidu, V. (2018). Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. Behavioural Brain Research, 344, 73–84CrossRef

Athira, K., Wahul, A. B., Soren, K., Das, T., Dey, S., Samudrala, P. K., Kumar, A., Lahkar, M., & Chakravarty, S. (2021). Differential modulation of GR signaling and HDACs in the development of resilient/vulnerable phenotype and antidepressant-like response of vorinostat. Psychoneuroendocrinology, 124, 105083CrossRef

Atluri, V. S. R., Pilakka-Kanthikeel, S., Samikkannu, T., Sagar, V., Kurapati, K. R. V., Saxena, S. K., Yndart, A., Raymond, A., Ding, H., & Hernandez, O. (2014). Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: Role of nicotine in progression of HIV-associated neurocognitive disorder. Molecular Brain, 7(1), 37PubMedPubMedCentralCrossRef

Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., Jain, G., Capece, V., Burkhardt, S., & Navarro-Sala, M. (2015). HDAC inhibitor–dependent transcriptome and memory reinstatement in cognitive decline models. The Journal of Clinical Investigation, 125(9), 3572–3584PubMedPubMedCentralCrossRef

Berger, J., & Gärtner, J. (2006). X-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects. Biochimica et Biophysica Acta B, 1763(12), 1721–1732CrossRef

Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., & Rios, M. (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science, 311(5762), 864–868PubMedCrossRef

Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007). Distribution of histone deacetylases 1–11 in the rat brain. Journal of Molecular Neuroscience, 31(1), 47–58PubMedCrossRef

Buchwald, M., Krämer, O. H., & Heinzel, T. (2009). HDACi–targets beyond chromatin. Cancer Letters, 280(2), 160–167PubMedCrossRef

Cenik, B., Sephton, C. F., Dewey, C. M., Xian, X., Wei, S., Yu, K., Niu, W., Coppola, G., Coughlin, S. E., & Lee, S. E. (2011). Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription rational therapeutic approach to frontotemporal dementia. Journal of Biological Chemistry, 286(18), 16101–16108CrossRef

Chakravarty, S., Bhat, U. A., Reddy, R. G., Gupta, P., & Kumar, A. (2014a). Histone deacetylase inhibitors and psychiatric disorders. Epigenetics in Psychiatry, 2, 515–544CrossRef

Chakravarty, S., Pathak, S. S., Maitra, S., Khandelwal, N., Chandra, K. B., & Kumar, A. (2014b). Epigenetic regulatory mechanisms in stress-induced behavior. International Review of Neurobiology., 115, 117–154PubMedCrossRef

Chandran, P., Kavalakatt, A., Malarvizhi, G. L., Vasanthakumari, D. R. V. N., Retnakumari, A. P., Sidharthan, N., Pavithran, K., Nair, S., & Koyakutty, M. (2014). Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomedicine: Nanotechnology, Biology and Medicine, 10(4), 721–732CrossRef

Chen, S., Wu, H., Ossola, B., Schendzielorz, N., Wilson, B. C., Chu, C.-H., Chen, S., Wang, Q., Zhang, D., & Qian, L. (2012). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. British Journal of Pharmacology, 165(2), 494–505PubMedPubMedCentralCrossRef

Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325(5942), 834–840PubMedCrossRef

Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., & Wu, E. Y. (2009). Antidepressant actions of histone deacetylase inhibitors. Journal of Neuroscience, 29(37), 11451–11460PubMedCrossRef

Cuadrado-Tejedor, M., Garcia-Barroso, C., Sanzhez-Arias, J., Mederos, S., Rabal, O., Ugarte, A., Franco, R., Pascual-Lucas, M., Segura, V., & Perea, G. (2015). Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease. Clinical Epigenetics, 7(1), 108PubMedPubMedCentralCrossRef

De Ruijter, A. J., Van Gennip, A. H., Caron, H. N., Stephan, K., & Van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochemical Journal, 370(3), 737–749PubMedCentralCrossRef

De Souza, C. (2015). P Chatterji B: HDAC inhibitors as novel anti-cancer therapeutics. Recent Patents on Anti-cancer Drug Discovery, 10(2), 145–162PubMedCrossRef

De Souza, C., Lindstrom, A. R., Ma, Z., & Chatterji, B. P. (2020). Nanomaterials as potential transporters of HDAC inhibitors. Medicine in Drug Discovery, 6, 100040CrossRef

Di, X.-J., Han, D.-Y., Wang, Y.-J., Chance, M. R., & Mu, T.-W. (2013). SAHA enhances proteostasis of epilepsy-associated α1 (A322D) β2γ2 GABAA receptors. Chemistry & Biology, 20(12), 1456–1468CrossRef

Didonna, A., & Opal, P. (2015). The promise and perils of HDAC inhibitors in neurodegeneration. Annals of Clinical and Translational Neurology, 2(1), 79–101PubMedCrossRef

Dokmanovic, M., Clarke, C., & Marks, P. A. (2007). Histone deacetylase inhibitors: Overview and perspectives. Molecular Cancer Research, 5(10), 981–989PubMedCrossRef

Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology, 45, 495–528PubMedCrossRef

Durisic, N., Keramidas, A., Dixon, C. L., & Lynch, J. W. (2018). SAHA (vorinostat) corrects inhibitory synaptic deficits caused by missense epilepsy mutations to the GABAA receptor γ2 subunit. Frontiers in Molecular Neuroscience, 11, 89PubMedPubMedCentralCrossRef

Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. International Journal of Molecular Sciences, 18(7), 1414PubMedCentralCrossRef

Eyüpoglu, I. Y., Hahnen, E., Buslei, R., Siebzehnrübl, F. A., Savaskan, N. E., Lüders, M., Tränkle, C., Wick, W., Weller, M., & Fahlbusch, R. (2005). Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. Journal of Neurochemistry, 93(4), 992–999PubMedCrossRef

Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006). Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Molecular Pharmacology, 70(6), 1876–1884PubMedCrossRef

Faria Freitas, M., Cuendet, M., & Bertrand, P. (2018). HDAC inhibitors: a 2013–2017 patent survey. Expert Opinion on Therapeutic Patents, 28(5), 365–381CrossRef

Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401(6749), 188–193PubMedCrossRef

Fujita, Y., Morinobu, S., Takei, S., Fuchikami, M., Matsumoto, T., Yamamoto, S., & Yamawaki, S. (2012). Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. Journal of Psychiatric Research, 46(5), 635–643PubMedCrossRef

Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., & Fantin, V. R. (2009). Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. Journal of Clinical Oncology, 27(12), 2052PubMedPubMedCentralCrossRef

Gangisetty, O. & Murugan, S. (2016). Epigenetic modifications in neurological diseases: natural products as epigenetic modulators a treatment strategy. In The benefits of natural products for neurodegenerative diseases. (pp. 1–25). Springer.

Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Journal of Biological Chemistry, 277(28), 25748–25755CrossRef

Ge, Z., Da, Y., Xue, Z., Zhang, K., Zhuang, H., Peng, M., Li, Y., Li, W., Simard, A., & Hao, J. (2013). Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Experimental Neurology, 241, 56–66PubMedCrossRef

Gill, S. S. (2019). Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor. Google Patents.

Golden, S. A., Christoffel, D. J., Heshmati, M., Hodes, G. E., Magida, J., Davis, K., Cahill, M. E., Dias, C., Ribeiro, E., & Ables, J. L. (2013). Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nature Medicine, 19(3), 337PubMedPubMedCentralCrossRef

Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010). Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Molecular Pharmacology, 77(2), 126–135PubMedCrossRef

Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012). Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry, 4(4), 505–524PubMedCrossRef

Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., & Mazitschek, R. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459(7243), 55PubMedPubMedCentralCrossRef

Haberland, M., Montgomery, R. L., & Olson, E. N. (2009). The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nature Reviews Genetics, 10(1), 32PubMedPubMedCentralCrossRef

Hahnen, E., Eyüpoglu, I. Y., Brichta, L., Haastert, K., Tränkle, C., Siebzehnrübl, F. A., Riessland, M., Hölker, I., Claus, P., & Romstöck, J. (2006). In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. Journal of Neurochemistry, 98(1), 193–202PubMedCrossRef

Hanson, J. E., La, H., Plise, E., Chen, Y.-H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., & Leahy, E. (2013a). SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS ONE, 8(7), e69964PubMedPubMedCentralCrossRef

Hanson, J. E., La, H., Plise, E., Chen, Y.-H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., & Leahy, E. (2013b). SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS ONE, 8(7), e69968CrossRef

Hauke, J., Riessland, M., Lunke, S., Eyüpoglu, I. Y., Blümcke, I., El-Osta, A., Wirth, B., & Hahnen, E. (2009). Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Human Molecular Genetics, 18(2), 304–317PubMedCrossRef

Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., & Lowden, P. A. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proceedings of the National Academy of Sciences, 100(4), 2041–2046CrossRef

Hoodin, F., LaLonde, L., Errickson, J., Votruba, K., Kentor, R., Gatza, E., Reddy, P., & Choi, S. W. (2019). Cognitive function and quality of life in vorinostat-treated patients after matched unrelated donor myeloablative conditioning hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 25(2), 343–353PubMedCrossRef

Jakovcevski, M., & Akbarian, S. (2012). Epigenetic mechanisms in neurological disease. Nature Medicine, 18(8), 1194PubMedPubMedCentralCrossRef

Jayant, R. D., Atluri, V. S., Agudelo, M., Sagar, V., Kaushik, A., & Nair, M. (2015). Sustained-release nanoART formulation for the treatment of neuroAIDS. International Journal of Nanomedicine, 10, 1077PubMedPubMedCentralCrossRef

Jhelum, P., Karisetty, B., Kumar, A., & Chakravarty, S. (2017). Implications of epigenetic mechanisms and their targets in cerebral ischemia models. Current Neuropharmacology, 15(6), 815–830PubMedPubMedCentralCrossRef

Jochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M., Mazitschek, R., Van Duzer, J. H., Jones, S., & Berton, O. (2014). Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology, 39(2), 389PubMedCrossRef

Johnstone, R. W., & Licht, J. D. (2003). Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell, 4(1), 13–18PubMedCrossRef

Kazantsev, A. G., & Thompson, L. M. (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews Drug Discovery, 7(10), 854–868PubMedCrossRef

Kelly, W. K., O’Connor, O. A., Krug, M. L., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., & Schwartz, L. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23(17), 3923PubMedCrossRef

Kelly, W. K., Richon, V. M., O’Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., & Rosa, E. (2003). Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research, 9(10), 3578–3588PubMed

Kidd, S. K., & Schneider, J. S. (2010). Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Research, 1354, 172–178PubMedPubMedCentralCrossRef

Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology, 35(4), 870–880PubMedCrossRef

Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006). α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics, 15(20), 3012–3023PubMedCrossRef

Kretsovali, A., Hadjimichael, C., & Charmpilas, N. (2012). Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells International, 2012, 1–10CrossRef

Kuta, R., Larochelle, N., Fernandez, M., Pal, A., Minotti, S., Tibshirani, M., Louis, K. S., Gentil, B. J., Nalbantoglu, J. N., & Hermann, A. (2020). Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress and Chaperones, 1, 1–19

Kv, A., Madhana, R. M., Bais, A. K., Singh, V. B., Malik, A., Sinha, S., Lahkar, M., Kumar, P., & Samudrala, P. K. (2020). Cognitive improvement by vorinostat through modulation of endoplasmic reticulum stress in a corticosterone-induced chronic stress model in mice. ACS Chemical Neuroscience, 11(17), 2649–2657CrossRef

Lai, J.-I., Leman, L. J., Ku, S., Vickers, C. J., Olsen, C. A., Montero, A., Ghadiri, M. R., & Gottesfeld, J. M. (2017). Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells. Bioorganic & Medicinal Chemistry Letters, 27(15), 3289–3293CrossRef

Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S. M., & Varma, A. K. (2015). Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Research, 35(2), 615–625PubMedPubMedCentral

Li, S., Lu, X., Shao, Q., Chen, Z., Huang, Q., Jiao, Z., Huang, X., Yue, M., Peng, J., & Zhou, X. (2019). Early histone deacetylase inhibition mitigates ischemia/reperfusion brain injury by reducing microglia activation and modulating their phenotype. Frontiers in Neurology, 10, 893PubMedPubMedCentralCrossRef

Lindemann, R., Newbold, A., Whitecross, K., Cluse, L., Frew, A., Ellis, L., Williams, S., Wiegmans, A., Dear, A., & Scott, C. (2007). Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences, 104(19), 8071–8076CrossRef

Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009). Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise. Current Pharmaceutical Design, 15(34), 3940–3957PubMedCrossRef

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007). FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist, 12(10), 1247–1252PubMedCrossRef

Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, 25(1), 84–90PubMedCrossRef

Marks, P. A., & Dokmanovic, M. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert opinion on investigational drugs, 14(12), 1497–1511PubMedCrossRef

McLaughlin, F., & La Thangue, N. B. (2004). Histone deacetylase inhibitors open new doors in cancer therapy. Biochemical Pharmacology, 68(6), 1139–1144PubMedCrossRef

Meng, J., Li, Y., Camarillo, C., Yao, Y., Zhang, Y., Xu, C., & Jiang, L. (2014). The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS ONE, 9(1), e85570PubMedPubMedCentralCrossRef

Meng, J., Li, Y., Zhang, M., Li, W., Zhou, L., Wang, Q., Lin, L., Jiang, L., & Zhu, W. (2019). A combination of curcumin, vorinostat and silibinin reverses Aβ-induced nerve cell toxicity via activation of AKT-MDM2-p53 pathway. PeerJ, 7, e6716PubMedPubMedCentralCrossRef

Meylan, E. M., Halfon, O., Magistretti, P. J., & Cardinaux, J.-R. (2016). The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: possible relevance for treatment-resistant depression. Neuropharmacology, 107, 111–121PubMedPubMedCentralCrossRef

Mielcarek, M., Benn, C. L., Franklin, S. A., Smith, D. L., Woodman, B., Marks, P. A., & Bates, G. P. (2011). SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington’s disease. PLoS ONE, 6(11), e203CrossRef

Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., & Gu, X. (2004). Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proceedings of the National Academy of Sciences, 101(2), 540–545CrossRef

Mohamed, E. A., Hashim, I. I. A., Yusif, R. M., Suddek, G. M., Shaaban, A. A. A., & Badria, F. A. E. (2017). Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities. European Journal of Pharmaceutical Sciences, 96, 232–242PubMedCrossRef

Mohamed, E. A., Zhao, Y., Meshali, M. M., Remsberg, C. M., Borg, T. M., Foda, A. M. M., Takemoto, J. K., Sayre, C. L., Martinez, S. E., & Davies, N. M. (2012). Vorinostat with sustained exposure and high solubility in poly (ethylene glycol)-b-poly (dl-lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine. Journal of Pharmaceutical Sciences, 101(10), 3787–3798PubMedCrossRef

Morris, M. J., & Monteggia, L. M. (2013). Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. International Journal of Developmental Neuroscience, 31(6), 370–381PubMedPubMedCentralCrossRef

Mueller, S., Yang, X., Sottero, T. L., Gragg, A., Prasad, G., Polley, M.-Y., Weiss, W. A., Matthay, K. K., Davidoff, A. M., & DuBois, S. G. (2011). Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters, 306(2), 223–229PubMedPubMedCentralCrossRef

Munkacsi, A. B., Hammond, N., Schneider, R. T., Senanayake, D. S., Higaki, K., Lagutin, K., Bloor, S. J., Ory, D. S., Maue, R. A., & Chen, F. W. (2017). Normalization of hepatic homeostasis in the Npc1nmf164 mouse model of Niemann-Pick type C disease treated with the histone deacetylase inhibitor vorinostat. Journal of Biological Chemistry, 292(11), 4395–4410CrossRef

Musolino, P. L., Gong, Y., Snyder, J. M., Jimenez, S., Lok, J., Lo, E. H., Moser, A. B., Grabowski, E. F., Frosch, M. P., & Eichler, F. S. (2015). Brain endothelial dysfunction in cerebral adrenoleukodystrophy. Brain, 138(11), 3206–3220PubMedPubMedCentralCrossRef

Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2010). Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer’s disease. Neuroscience Letters, 475(2), 64–68PubMedCrossRef

Olsen, E., Kim, Y., Kuzel, T., Pacheco, T., Foss, F., Parker, S., Wang, J., Frankel, S., Lis, J., & Duvic, M. (2006). Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. Journal of Clinical Oncology, 24(18 suppl), 7500–7500CrossRef

Palmieri, D., Lockman, P. R., Thomas, F. C., Hua, E., Herring, J., Hargrave, E., Johnson, M., Flores, N., Qian, Y., & Vega-Valle, E. (2009). Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clinical Cancer Research, 15(19), 6148–6157PubMedPubMedCentralCrossRef

Peixoto, P., & Lansiaux, A. (2006). Histone-deacetylases inhibitors: from TSA to SAHA. Bulletin du Cancer, 93(1), 27–36PubMed

Pipalia, N. H., Subramanian, K., Mao, S., Ralph, H., Hutt, D. M., Scott, S. M., Balch, W. E., & Maxfield, F. R. (2017). Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. Journal of Lipid Research, 58(4), 695–708PubMedPubMedCentralCrossRef

Price, S., & Dyke, H. J. (2007). Histone deacetylase inhibitors: An analysis of recent patenting activity. Expert Opinion on Therapeutic Patents, 17(7), 745–765CrossRef

Rauniyar, N., Subramanian, K., Lavallée-Adam, M., Martínez-Bartolomé, S., Balch, W. E., & Yates, J. R. (2015). Quantitative proteomics of human fibroblasts with I1061T mutation in Niemann-Pick C1 (NPC1) protein provides insights into the disease pathogenesis. Molecular & Cellular Proteomics, 14(7), 1734–1749CrossRef

Reddy, R. G., Surineni, G., Bhattacharya, D., Marvadi, S. K., Sagar, A., Kalle, A. M., Kumar, A., Kantevari, S., & Chakravarty, S. (2019). Crafting carbazole-based vorinostat and tubastatin-A-like histone deacetylase (HDAC) inhibitors with potent in vitro and in vivo neuroactive functions. ACS Omega, 4(17), 17279–17294PubMedPubMedCentralCrossRef

Richon, V., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R., & Marks, P. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings of the National Academy of Sciences, 93(12), 5705–5708CrossRef

Riessland, M., Ackermann, B., Förster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., & Hahnen, E. (2010). SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Human Molecular Genetics, 19(8), 1492–1506PubMedCrossRef

Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: A systematic review of observational studies. Journal of the National Cancer Institute, 103(1), 61–76PubMedCrossRef

Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., & Barker, D. D. (2013). A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE, 8(8), e71323PubMedPubMedCentralCrossRef

Seo, Y. J., Kang, Y., Muench, L., Reid, A., Caesar, S., Jean, L., Wagner, F., Holson, E., Haggarty, S. J., & Weiss, P. (2014). Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. ACS Chemical Neuroscience, 5(7), 588–596PubMedPubMedCentralCrossRef

Shahbazian, M. D., & Grunstein, M. (2007). Functions of site-specific histone acetylation and deacetylation. Annual Review of Biochemistry, 76, 75–100PubMedCrossRef

She, A., Kurtser, I., Reis, S. A., Hennig, K., Lai, J., Lang, A., Zhao, W.-N., Mazitschek, R., Dickerson, B. C., & Herz, J. (2017). Selectivity and kinetic requirements of HDAC inhibitors as progranulin enhancers for treating frontotemporal dementia. Cell Chemical Biology, 24(7), 892–906PubMedPubMedCentralCrossRef

Shim, H., Wei, L., Holder, C. A., Guo, Y., Hu, X. P., Miller, A. H., & Olson, J. J. (2014). Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. American Journal of Roentgenology, 203(2), W158–W165PubMedCrossRef

Sukumari-Ramesh, S., Alleyne, C. H., & Dhandapani, K. M. (2016). The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) confers acute neuroprotection after intracerebral hemorrhage in mice. Translational Stroke Research, 7(2), 141–148PubMedCrossRef

Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018). Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Frontiers in Oncology, 8, 92PubMedPubMedCentralCrossRef

Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., & Marks, P. A. (1975). Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proceedings of the National Academy of Sciences, 72(3), 1003–1006CrossRef

Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience, 9(4), 519PubMedCrossRef

Uchida, S., Hara, K., Kobayashi, A., Otsuki, K., Yamagata, H., Hobara, T., Suzuki, T., Miyata, N., & Watanabe, Y. (2011). Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron, 69(2), 359–372PubMedCrossRef

Ugur, H. C., Ramakrishna, N., Bello, L., Menon, L. G., Kim, S.-K., Black, P. M., & Carroll, R. S. (2007). Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of Neuro-Oncology, 83(3), 267–275PubMedCrossRef

VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011). Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. The Journal of Antibiotics, 64(8), 525PubMedPubMedCentralCrossRef

Wang, Y., Tu, S., Steffen, D., & Xiong, M. P. (2014). Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats. Journal of Pharmacy & Pharmaceutical Sciences, 17(4), 583CrossRef

Wash, P. L., Hoffman, T. Z., Wiley, B. M., Bonnefous, C., Smith, N. D., Sertic, M. S., Lawrence, C. M., Symons, K. T., Nguyen, P.-M., & Lustig, K. D. (2008). α-Mercaptoketone based histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18(24), 6482–6485CrossRef

Wei, L., Hong, S., Yoon, Y., Hwang, S. N., Park, J. C., Zhang, Z., Olson, J. J., Hu, X. P., & Shim, H. (2012). Early prediction of response to Vorinostat in an orthotopic rat glioma model. NMR in Biomedicine, 25(9), 1104–1111PubMedPubMedCentralCrossRef

Xu, J., Shi, J., Zhang, J., & Zhang, Y. (2018). Vorinostat: a histone deacetylases (HDAC) inhibitor ameliorates traumatic brain injury by inducing iNOS/Nrf2/ARE pathway. Folia Neuropathologica, 56, 179–186PubMedCrossRef

Yang, C., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R. O., & Zhuang, Z. (2013). Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences, 110(3), 966–971CrossRef

Yin, D., Ong, J. M., Hu, J., Desmond, J. C., Kawamata, N., Konda, B. M., Black, K. L., & Koeffler, H. P. (2007). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo. Clinical Cancer Research, 13(3), 1045–1052PubMedCrossRef

Yu, Q., Feng, N., Hu, Y., Luo, F., Zhao, W., Zhao, W., Liu, Z., Li, M., Xu, L., & Wu, L. (2019). Suberoylanilide hydroxamic acid (SAHA) alleviates the learning and memory impairment in rat offspring caused by maternal sevoflurane exposure during late gestation. The Journal of Toxicological Sciences, 44(3), 177–189PubMedCrossRef

Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017). The search for potent, small-molecule HDACIs in cancer treatment: A decade after vorinostat. Medicinal Research Reviews, 37(6), 1373–1428PubMedCrossRef

Ziemka-Nalecz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018). Histone deacetylase inhibitors: A therapeutic key in neurological disorders? Journal of Neuropathology & Experimental Neurology, 77(10), 855–870CrossRef

Zierfuss, B., Weinhofer, I., Kühl, J. S., Köhler, W., Bley, A., Zauner, K., Binder, J., Martinović, K., Seiser, C., & Hertzberg, C. (2020). Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. Annals of Clinical and Translational Neurology, 7, 639–652PubMedPubMedCentralCrossRef

Titel: Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
verfasst von: K. V. Athira
Prashant Sadanandan
Sumana Chakravarty
Publikationsdatum: 04.05.2021
Verlag: Springer US
Erschienen in: NeuroMolecular Medicine / Ausgabe 4/2021
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-021-08660-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Retraction Note to: Methylation and Expression Patterns of Tropomyosin-Related Kinase Genes in Different Grades of Glioma

Assessment of Peripheral Blood Lymphocytes in Parents of Autistic Children by Cytokinesis Block Micronucleus Assay

Correction to: Specific Susceptibility to COVID-19 in Adults with Down Syndrome

Ubiquitination of p21 by E3 Ligase TRIM21 Promotes the Proliferation of Human Neuroblastoma Cells

IL-2/IL-2R Antibody Complex Enhances Treg-Induced Neuroprotection by Dampening TNF-α Inflammation in an In Vitro Stroke Model